Hikma Pharmaceuticals PLC (LON:HIK) Receives GBX 2,585 Consensus Price Target from Brokerages

Hikma Pharmaceuticals PLC (LON:HIKGet Rating) has earned an average rating of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is GBX 2,642 ($32.57).

HIK has been the subject of a number of recent analyst reports. Barclays reaffirmed an “overweight” rating and set a GBX 2,800 ($34.52) target price on shares of Hikma Pharmaceuticals in a research report on Monday, May 9th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Hikma Pharmaceuticals in a research note on Monday, January 17th. Finally, Morgan Stanley reiterated an “equal weight” rating on shares of Hikma Pharmaceuticals in a research note on Wednesday.

LON:HIK traded up GBX 27 ($0.33) on Monday, hitting GBX 1,724 ($21.26). 1,306,357 shares of the company’s stock traded hands, compared to its average volume of 635,365. The company has a market cap of £3.90 billion and a PE ratio of 11.76. The company has a current ratio of 2.06, a quick ratio of 1.31 and a debt-to-equity ratio of 34.29. Hikma Pharmaceuticals has a 1 year low of GBX 1,651.50 ($20.36) and a 1 year high of GBX 2,703 ($33.33). The firm has a 50-day moving average price of GBX 1,984.66 and a 200-day moving average price of GBX 2,099.18.

The firm also recently announced a dividend, which was paid on Thursday, April 28th. Stockholders of record on Thursday, March 17th were paid a dividend of $0.36 per share. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.18. This represents a dividend yield of 1.32%. The ex-dividend date of this dividend was Thursday, March 17th. Hikma Pharmaceuticals’s payout ratio is currently 0.35%.

In other news, insider Sigurdur Olafsson sold 27,498 shares of the business’s stock in a transaction on Monday, March 14th. The stock was sold at an average price of GBX 1,988 ($24.51), for a total transaction of £546,660.24 ($673,973.91). Also, insider Douglas Hurt bought 1,500 shares of the stock in a transaction on Thursday, March 3rd. The stock was purchased at an average cost of GBX 1,954 ($24.09) per share, with a total value of £29,310 ($36,136.11).

Hikma Pharmaceuticals Company Profile (Get Rating)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.

Read More

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.